OLMA vs. GERN, VERA, AMPH, AGIO, AMRX, RCKT, CPRX, GLPG, ZLAB, and KROS
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Zai Lab (ZLAB), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
In the previous week, Geron had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Geron and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.25 beat Geron's score of 0.95 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Olema Pharmaceuticals has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Geron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Geron received 455 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 61.54% of users gave Olema Pharmaceuticals an outperform vote.
Olema Pharmaceuticals presently has a consensus target price of $22.00, suggesting a potential upside of 127.27%. Geron has a consensus target price of $6.10, suggesting a potential upside of 71.83%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Geron.
Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
Olema Pharmaceuticals has a net margin of 0.00% compared to Geron's net margin of -38,730.00%. Olema Pharmaceuticals' return on equity of -42.87% beat Geron's return on equity.
Summary
Olema Pharmaceuticals beats Geron on 12 of the 17 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
